AdenoCure is an innovative in vitro assay platform developed to accelerate the discovery of therapeutic strategies for chemo-resistant cancers. At its core is a recombinant adenoviral construct (Ad-MBRG) encoding the tumor suppressor genes MOAP-1, BAX, RASSF1A, and EGFP, designed to restore apoptotic signaling pathways in cancer cells. This unique approach enables the creation of sensitized cell models that better represent the biological characteristics of drug-resistant tumors.

AdenoCure 3X, the first-generation kit, features a 2D in vitro cell culture assay designed for rapid, reproducible screening of potential anti-cancer compounds. By reactivating apoptosis through Ad-MBRG-mediated gene expression, AdenoCure 3X provides a powerful tool for identifying compounds that enhance therapeutic sensitivity and overcome chemoresistance in conventional monolayer cultures.

AdenoCure 3D, the second-generation advancement, extends this innovation into a 3D spheroid culture system that closely mimics the in vivo tumor microenvironment. Incorporating the same adenoviral gene delivery mechanism, AdenoCure 3D offers a more physiologically relevant platform for evaluating drug synergy, resistance reversal, and tumor response dynamics. This next-generation model bridges the gap between in vitro discovery and in vivo relevance, supporting translational research in cancer therapeutics.